Management of idiopathic membranous nephropathy with intravenous cyclophosphamide

Manejo de la nefropatía membranosa idiopática con ciclofosfamida endovenosa

Main Article Content

Carlos Rosselli SanMartin
Camilo Alfonso Vallejo Castillo
Hugo Enrique Pérez

Abstract

Introduction: primary glomerular diseases represent the third cause of chronic kidney disease, being membranous nephropathy (MN) the most frequent cause of nephrotic syndrome in Colombia. Intravenous cyclophosphamide is a treatment option for MN, which has not been described in our population. Objective: to determine the response of idiopathic membranous nephropathy (IMN) to IV cyclophosphamide at Hospital de San José de Bogotá from January 2000 to January 2019.  Methodology: case series study which included all adult patients with IMN diagnosed by renal biopsy treated with IV cyclophosphamide in the described period. Results: eight patients were included in the study of which 50% were women, median age at presentation was 32.5 (IQR: 26-45) years. 100% of patients experienced partial or complete remission, as follows: 62.5% complete remission and 37.5% partial remission. Increase in the median glomerular filtration rate after the use of IV cyclophosphamide was 9 (IQR: 1-20.2) mL/min/1.73 m2. Renal survival rate was 100% and the relapse rate was 12.5%. Conclusions: monthly IV cyclophosphamide is a treatment option for IMN, attaining 100% partial or complete remission, using a median cumulative dose of 93 (IQR: 65.6-125) mg/k.  

Keywords:

Downloads

Download data is not yet available.

Article Details

References

SantaCruz P, Dorta L. La carga de la enfermedad renal crónica (ERC) sobre la mortalidad de la población. ¿los datos disponibles reflejan la realidad?. Nefrología. 2006;26(4):419-20.

Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization. 2018;96(6):414-22D. doi: 10.2471/BLT.17.206441 DOI: https://doi.org/10.2471/BLT.17.206441

Bello AK, Johnson DW, Feehally J, Harris D, Jindal K, Lunney M, et al. Global Kidney Health Atlas (GKHA): design and methods. Kidney Int. Suppl. 2017;7(2):145-53. doi: 10.1016/j.kisu.2017.08.001 DOI: https://doi.org/10.1016/j.kisu.2017.08.001

Situación de la Enfermedad Renal Crónica, la Hipertensión Arterial y la Diabetes Mellitus en Colombia 2017-2018 Bogotá: Fondo Colombiano de Enfermedades de Alto Costo; 2018. p. 293.

Guillermo García Herrera H, Restrepo C, Alberto Buitrago Villa C. Características clínicas e histológicas de las enfermedades parenquimatosas renales en una muestra de biopsias renales obtenidas entre el año 2002 y el 2017 en el departamento de Caldas, Colombia. Rev. Colomb. Nefrol. 2018;5(2):107-117. doi: 10.22265/acnef.0.0.300 DOI: https://doi.org/10.22265/acnef.0.0.300

Yesid Coronado C, Echeverry I. Clinicopathological description of glomerular diseases. Acta médica colombiana. 2016;41(2):125-9.

Glassock RJ. The Pathogenesis of Idiopathic Membranous Nephropathy: A 50-Year Odyssey. Am J Kidney Dis. 2010;56(1):157-67. doi: 10.1053/j.ajkd.2010.01.008 DOI: https://doi.org/10.1053/j.ajkd.2010.01.008

Pendergraft WF, Nachman PH, Jennette JC, Falk RJ. Enfermedad glomerular primaria. In: Skorecki KMDFF, Chertow GMMD, Marsden PAMD, Taal MWMMMDFCPF, Yu ASLMD, Wasser WGMD, editors. Brenner y Rector El riñón2018. p. 1012-90.

Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J Title. 2019;95(1119):23-31. doi: 10.1136/postgradmedj-2018-135729 DOI: https://doi.org/10.1136/postgradmedj-2018-135729

Beck LH, Jr., Bonegio Rg Fau - Lambeau G, Lambeau G Fau - Beck DM, Beck Dm Fau - Powell DW, Powell Dw Fau - Cummins TD, Cummins Td Fau - Klein JB, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/NEJMoa0810457 DOI: https://doi.org/10.1056/NEJMoa0810457

Tomas NM, Beck LH, Jr., Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371(24):2277-2287. doi: 10.1056/NEJMoa1409354 DOI: https://doi.org/10.1056/NEJMoa1409354

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International. 2019;95(2):268-80. doi: 10.1016/j.kint.2018.10.018 DOI: https://doi.org/10.36485/1561-6274-2020-24-2-22-41

Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, et al. Controlled Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous Nephropathy. N Engl J Med. 1984;310(15):946-50. doi: 10.1056/NEJM198404123101503 DOI: https://doi.org/10.1056/NEJM198404123101503

Aldana I, Diazgranados I, Gustavo AM, García R. Respuestas al esquema ponticelli en pacientes con nefropat+ia membranosa idiopatica. Barranquilla 2011-2013. Barranquilla 2011- 2013. Biociencias. 2014;9(1):23-9.

Mathrani V, Alejmi A, Griffin S, Roberts G. Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy. Clin Kidney J. 2017;10(4):450-454. doi: 10.1093/ckj/sfw152 DOI: https://doi.org/10.1093/ckj/sfw152

Gustavo AM, Gaviria Garcia G, Sierra Llamas C, Elena Lastre-Amell G. Valorar el seguimiento y cumplimiento integral de adherencia al tratamiento en pacientes con nefritis lúpica. Investig Enferm Imagen Desarr. 2018;20(1). doi: 10.11144/Javeriana.ie20-1.vsci DOI: https://doi.org/10.11144/Javeriana.ie20-1.vsci

Thompson A, Cattran DC, Blank M, Nachman PH. Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy. J Am Soc Nephrol. 2015;26(12):2930-7. doi: 10.1681/ASN.2015010091 DOI: https://doi.org/10.1681/ASN.2015010091

Ponticelli C, Altieri P Fau - Scolari F, Scolari F Fau - Passerini P, Passerini P Fau - Roccatello D, Roccatello D Fau - Cesana B, Cesana B Fau - Melis P, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9(3):444-50. doi: 10.1681/ASN.V93444 DOI: https://doi.org/10.1681/ASN.V93444

de Groot K, Harper L Fau - Jayne DRW, Jayne Dr Fau - Flores Suarez LF, Flores Suarez Lf Fau - Gregorini G, Gregorini G Fau - Gross WL, Gross Wl Fau - Luqmani R, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. (1539- Ann Intern Med. 2009;150(10):670-80. doi: 10.7326/0003-4819-150-10-200905190-00004 DOI: https://doi.org/10.7326/0003-4819-150-10-200905190-00004

Kanigicherla DAK, Hamilton P, Czapla K, Brenchley PE. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy. Nephrology (Carlton). 2018;23(1):60-68. doi: 10.1111/nep.12955 DOI: https://doi.org/10.1111/nep.12955

Faurschou M, Sorensen Ij Fau - Mellemkjaer L, Mellemkjaer L Fau – Loft AGR, Loft Ag Fau - Thomsen BS, Thomsen Bs Fau - Tvede N, Tvede N Fau - Baslund B, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-5

Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non- Hodgkin’s lymphoma. J Natl Cancer Inst. 1995;87(7):524-30. doi: 10.1093/jnci/87.7.524 DOI: https://doi.org/10.1093/jnci/87.7.524

Muller-Deile J, Schiffer L, Hiss M, Haller H, Schiffer M. A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest. 2015;45(12):1260-9. doi: 10.1111/eci.12545 DOI: https://doi.org/10.1111/eci.12545

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi: 10.1056/NEJMoa1814427 DOI: https://doi.org/10.1056/NEJMoa1814427

Ruggenenti P, Remuzzi G. A First Step toward a New Approach to Treating Membranous Nephropathy. N Engl J Med. 2019;381(1):86-88. doi: 10.1056/NEJMe1906666 DOI: https://doi.org/10.1056/NEJMe1906666

Citado por